Natera (NTRA) Stock Price, News & Analysis

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings or view top-rated stocks.

14 brokers have issued 1 year price targets for Natera's stock. Their NTRA share price targets range from $66.00 to $120.00. On average, they expect the company's stock price to reach $86.40 in the next year. This suggests that the stock has a possible downside of 4.4%.
View analysts price targets for NTRA or view top-rated stocks among Wall Street analysts.

Natera's stock was trading at $62.64 at the start of the year. Since then, NTRA shares have increased by 44.2% and is now trading at $90.33.
View the best growth stocks for 2024 here.

Natera saw a drop in short interest in March. As of March 31st, there was short interest totaling 6,250,000 shares, a drop of 21.4% from the March 15th total of 7,950,000 shares. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is presently 4.1 days.
View Natera's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NTRA earnings forecast.

Natera, Inc. (NASDAQ:NTRA) posted its quarterly earnings data on Wednesday, February, 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.73) by $0.09. The medical research company earned $311.11 million during the quarter, compared to the consensus estimate of $300.38 million. Natera had a negative net margin of 40.16% and a negative trailing twelve-month return on equity of 62.19%.

ETFs with the largest weight of Natera (NASDAQ:NTRA) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Alger Mid Cap 40 ETF (FRTY), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Alger 35 ETF (ATFV), American Century Mid Cap Growth Impact (MID), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and ROBO Global Healthcare Technology and Innovation ETF (HTEC).

Natera updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

Natera (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Natera's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Artemis Investment Management LLP (0.19%), Banque Cantonale Vaudoise (0.01%), Wealth Enhancement Advisory Services LLC (0.00%), Park Avenue Securities LLC (0.00%), Tlwm (0.00%) and Fulton Bank N.A. (0.00%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Solomon Moshkevich, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends.

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.